Cambridge · Seed–Series A · 7 people tracked
Also known as Flagship Pioneering Special · FLAGSHIP PIONEERING, LLC · Flagship Ventures Management, Inc.
Find your way into Flagship Pioneering
9,858 people in our graph share verified history with the Flagship Pioneering team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Flagship Pioneering has spent over 25 years pursuing breakthroughs at the frontiers of science, aiming to make the seemingly impossible possible for the benefit of people and the planet. The firm emphasizes a culture of fearless exploration and discovery, building companies and pioneering advances that push the boundaries of knowledge. Its work is centered on both scientific breakthroughs and the people who drive them.
Source: firm website, verified Sep 1, 2026.
Team · 7 people
from the firm's website & curated & public directories
Founder mafia
The Flagship Pioneering mafia →20 people who came through Flagship Pioneering went on to found or lead other companies.
+ 8 more
What they invest in
from 44 of 58 portfolio companiesBiotech ×33AI & Machine Learning ×21Deep Tech ×16Healthtech ×9Medical Devices ×9Digital Health ×6Enterprise Software ×5SaaS ×5
HQs:United States×24Spain×1Rwanda×1Sweden×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×72 founders×23 founders×24+ founders×2
Where their founders worked beforefrom 13 founders with career history
Generate Biomedicines ×3Repertoire Immune Medicines ×2Ring Therapeutics ×2Rubius Therapeutics ×2
Investments · 58 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 42024 · 12023 · 12021 · 22019 · 12018 · 22017 · 22015 · 32014 · 219 dated
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.
AI & Machine LearningBiotechDeep TechSomerville, US
Gevorg Grigoryan(Co-Founder & Chief Technology Officer)in
Co-investorsARCH Venture PartnersMarch Capital PartnersAlaska Permanent Fund CorporationALTITUDE LIFE SCIENCE VENTURESNVenturesT. Rowe Price
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)in
Co-investorsRA CapitalSofinnova Ventures
BiotechCambridge, US
John Aunins(Executive Officer)Eric D. Shaff(Executive Officer)David Cook(Executive Officer)Roger J. Pomerantz(Executive Officer, Director)
Board seatDavid BerryNoubar Afeyan· per SEC Form D · $65M raise · filed Jan 2015
CIBO provides a software platform for designing, deploying, and measuring regenerative agriculture and conservation programs, including workflow automation, scientific modeling, impact reporting, and a network of advisors managing grower engagement.
AgTechAI & Machine LearningClimate TechSaaSCambridge, US
Bruno Basso(Co-Founder and Special Advisor)David Worn(Executive Officer, Director)inBarry Martin(Executive Officer)inRyan Richt(Executive Officer)inDale Sorensen(Executive Officer)Sunand Menon(Executive Chairman & CEO)in
Board seatIgnacio MartinezStephen BerensonNoubar Afeyan· per SEC Form D
Co-investorsGeneration Investment ManagementStage 1 Ventures
Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function.
AI & Machine LearningBiotechDeep Tech
Avak Kahvejian(Chairman (Founder / founding CEO))inMike(Chief Innovation Officer & Co-Founder)Jaclyn Dunphy(Co-Founder & Senior Director of Strategy and Research Operations)inMaria-Chiara Magnone(Chief Scientific Officer)in
Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties.
AI & Machine LearningBiotechDeep TechHealthtech
Lovisa Afzelius(Executive Chair & Founding CEO)inMichelle Werner(CEO)inJoanne Protano(President & Chief Financial Officer)inDave Hava(Chief Scientific Officer)inNerissa Kreher(Chief Medical Officer)inCaroline Köhrer(SVP, Discovery Platform)in
Apriori Bio applies AI/ML combined with biological insights to predict how viruses evolve and to design vaccines, assessing their expected performance before clinical trials.
AI & Machine LearningBiotechDeep TechHealthtech
Cloud ComputingData & InfrastructureEnterprise SoftwareAustin, US
Jonathan Ring(Executive Officer, Director)Paul Carpentier(Director)George Teixeira(Chairman of the Board, Co-founder)inJohn Bocskor(Former DataCore Vice President, Product Development and Co-founder)inMark Goros(Executive Officer, Director)Dave Zabrowski(Chief Executive Officer)in
Co-investorsInsight PartnersNew Science Ventures
Etiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention.
AI & Machine LearningBiotechLongevity
Katharine von Herrmann(Co-founder)inAvak Kahvejian(Founding Team; Founding CEO)inNoubar Afeyan(Founding Team)Scott Lipnick(Founding Team)inTorben Straight Nissen(Founding Team; Board Director)inYann Echelard(Founding Team; Chief Operating Officer)
Inari applies artificial intelligence and gene editing to accelerate plant breeding, delivering crop improvement solutions for farmers focused on soybeans, corn, and wheat across broadacre agriculture.
AgTechAI & Machine LearningBiotechCambridge, US
Lisa Safarian(CEO)inStuart Brown(Chief Financial Officer)Pierre-Etienne Boin(Secretary and General Counsel)inPonsi Trivisvavet(President and Chief Executive Officer)in
BoardRobert Berendes, Ph.D.(Director)Ignacio Martinez(Director)in
Co-investorsAcre Venture PartnersCongruent VenturesG Squared
DataCore develops software-defined storage and object storage solutions for enterprises to virtualize and manage storage infrastructure across primary, secondary, and archive environments.
Cloud ComputingData & InfrastructureEnterprise Software
George Teixeira(Chairman of the Board, Co-founder)inJohn Bocskor(Co-founder, Former Vice President of Product Development)in
Co-investorsInsight PartnersPartners for GrowthPartners for Growth (PFG)Utiliti GroupAME Cloud Ventures
Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action.
AI & Machine LearningBiotechDeep TechMedical Devices
Co-investorsGlobal Brain
Montai is a drug discovery company that combines human biology, chemistry, computational biology, and machine learning to identify connections between chemistry and disease pathways and develop new therapies.
AI & Machine LearningBiotechDeep TechHealthtech
ProFound Therapeutics discovers and develops therapeutic candidates by analyzing the expanded human proteome, identifying novel proteins from previously uncharacterized genetic sequences that can serve as drug targets for cancer, immune disorders, and metabolic diseases.
AI & Machine LearningBiotechDeep Tech
Avak Kahvejian(Co-founder, Chairman)inYann Echelard(Co-founder)Vini Mani(Co-founder)inErica Weinstein(Co-founder)in
BoardNoubar Afeyan
Co-investorsModi Ventures
Quotient is a biotechnology company applying somatic genetics research to R&D, developing its work through a proprietary platform.
AI & Machine LearningBiotechDeep Tech
Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.
AI & Machine LearningBiotechDeep TechCambridge, US
John Mendlein(Executive Chairman)
Co-investorsNextech InvestQuan Capital
Terrana Biosciences is an agricultural biotech company applying RNA technology to plant health, developing a platform that gives crops new traits such as drought tolerance and shorter ripening times.
AgTechAI & Machine LearningBiotechDeep Tech
Noubar Afeyan(Founder)Ignacio Martinez(Founder)inRyan Rapp(Founder & CEO)in
Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates.
AI & Machine LearningBiotechDeep TechCambridge, US
Yasir Al-Wakeel(CEO)in
Co-investorsARCH Venture Partners
BG Medicine develops and commercializes cardiovascular diagnostic tests to assess heart failure risk and predict cardiovascular events.
BiotechDigital HealthHealthtechMedical DevicesWaltham, US
Stephen Hall(Executive Officer)inPaul Sohmer(Executive Officer, Director)Aram Adourian(Executive Officer)Harry Wilcox(Director)Paul R. Sohmer, M.D.(President and CEO)
Board seatNoubar Afeyan· per SEC Form D · $2.5M raise · filed May 2015
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)
BoardSteven Gillis(Director)Eric Lander(Director)
Board seatNoubar Afeyan· per SEC Form D · filed Nov 2015
Co-investorsARCH Venture PartnersEcoR1 Capital
Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
BiotechDeep TechMedical DevicesCambridge, US
Robert Langer(Director)Noubar Afeyan, Ph.D.(Co-founder and Chairman, Moderna; CEO, Flagship Pioneering)Lorence Kim(Executive Officer)inJames R. Kasinger(Executive Officer)inStephen Hoge(Executive Officer)in
BoardStephane Bancel(Chief Executive Officer)in
Board seatNoubar Afeyan· per SEC Form D
Co-investorsAglae VenturesBlackstone Life SciencesFPVKhosla VenturesPremji InvestRA Capital
BiotechCambridge, US
Robert Connelly(Executive Officer, Director)Garry Menzel(Executive Officer)Jeff Moore(Executive Officer)
BoardJohn Mendlein(Director)
Board seatDavid BerryNoubar Afeyan· per SEC Form D · filed Feb 2016
Co-investorsFidelity InvestmentsFlagship Ventures
BiotechCambridge, US
Torben Straight Nissen(Executive Officer, Director)inJoanne Protano(Executive Officer)inDavid Epstein(Director)Harvey F. Lodish(Director)Michael Rosenblatt(Director)Roger Pomerantz(Director)
Board seatNoubar Afeyan· per SEC Form D
Co-investorsFlagship VenturesKendall Capital Partners
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Director)Steve Harr(President and Chief Executive Officer)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
Board seatGeoffrey von Maltzahn· per SEC Form D
Co-investorsAmerican Family VenturesARCH Venture PartnersF-Prime CapitalInnovating CapitalJDRF T1D FundManta Ray Ventures+1 more
Ampersand provides a declarative integration framework for building bi-directional, customer-configurable product integrations with third-party applications.
Developer ToolsEnterprise SoftwareSaaS
Lauren Long(Founder)in
Co-investors2.12 AngelsMatrixFlex Capital Partners
Ampersand provides deposit administration services and operates as a national authority in the deposit management sector, serving depositors and financial institutions.
Enterprise SoftwareFintechSaaS
Co-investorsPatriot Financial PartnersJAM FINTOPFINTOP Capital
Ampersand builds electric motorcycles, battery packs, swap stations, and AmperOps fleet management software for motorcycle taxi (boda) drivers in Africa, operating a battery-swapping network for commercial e-motos.
CleantechEnergyMobility & Transportation
Co-investorsBeyond CapitalBeyond Capital VenturesBlue Haven InitiativeEcosystem Integrity FundFactor[e] VenturesAlphaMundi Group+2 more
MIT is an educational and research institution in Cambridge, Massachusetts, pursuing teaching, research, and innovation across science, engineering, and other fields.
BiotechEdTechCambridge, US
Co-investorsBeyond Earth VenturesFoundersX VenturesJIMCOLair East LabsMassChallenge MexicoSelvedge Venture
Cellarity develops medicines using artificial intelligence and single-cell biology to address disease at the cellular level rather than targeting individual disease markers.
AI & Machine LearningBiotechDeep TechMedical Devices
Co-investorsAhren Innovation CapitalManta Ray VenturesBlackRock
Cloudflare provides a global cloud network platform delivering security, performance, and development services through sixty-plus integrated services including SASE, application security, and full-stack development infrastructure.
Cloud ComputingCybersecurityDeveloper ToolsSan Francisco, US
Matthew Prince(Founder)inDane Knechtin
Co-investorsApposite CapitalCapitalGEQT VenturesIcon VenturesKhosla VenturesLocalGlobe+14 more
Rockaway Park, US
Yevgeniy Mordkovich(Executive Officer, Director)inBoris Mordkovich(Executive Officer, Director)
Co-investorsGV (Google Ventures)Kaiser Permanente Ventures
BiotechCambridge, US
Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)
BoardNoubar B. Afeyan, Ph.D.(Director)
Co-investorsSV Health InvestorsKaiser Permanente Ventures
Harbinger Health develops early cancer detection technology through its Harbinger HX platform, which embeds developmental biology into biomarker discovery, assay design, and model training to detect faint biological signals of early cancer in real-world samples.
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsCatalyst
Inari builds insurance infrastructure technology platforms that enable insurers, MGAs, and reinsurers to operate more efficiently through AI automation and integrations.
AI & Machine LearningEnterprise SoftwareInsurTechSaaSBarcelona, ES
Frank Perkins(Chief Executive Officer)
Co-investorsCriteria Venture Tech
Co-investorsInvestX
Co-investorsKickstart InnovationStage 1 Ventures
Korrus makes the OIO System, a circadian lighting ecosystem consisting of smart bulbs, a spectral-control app, and a light sensor that shift light spectrum through the day to support focus and alertness and remove blue light at night to aid sleep.
ConsumerHardwareWellness & Fitness
Co-investorsEastward Capital PartnersRichmond Global Ventures
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)
BoardALAN L. CRANE(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersLAVLG Technology VenturesLilly Asia VenturesBaillie Gifford+1 more
LILA Sciences builds AI systems for autonomous scientific research and discovery across medicine, materials, energy, and defense sectors.
AI & Machine LearningBiotechDeep TechSaaS
Co-investorsCatalio Capital Management, LPDauntless VenturesMarch Capital PartnersModi VenturesCollective GlobalIn-Q-Tel+1 more
Nobelprize.org provides open data about the Nobel Prizes and Nobel Laureates to developers through a REST API and as Linked Data (RDF/SPARQL).
Data & InfrastructureDeveloper ToolsEdTechImpact & Social GoodMedia & EntertainmentStockholm, SE
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Torben Straight Nissen(Chief Executive Officer)inAnthony Coyle(President, Research and Development)inRobert Andtbacka(Chief Medical Officer)inJohn Delyani(Chief Business Officer)inJan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)in
Co-investorsSoftBank Vision FundJDRF T1D Fund
Ring provides video doorbells and security cameras that allow homeowners to monitor their property and enhance security across indoor and outdoor spaces.
HardwareIoT
Jamie Siminoff(Founder)in
Co-investorsAmerican Family VenturesCRV (Charles River Ventures)Energy Impact PartnersFelicis VenturesGreen Meadow VenturesGrishin Robotics+8 more
Serif Biomedicines develops DNA-based therapies and nucleic acid delivery technologies for genetic medicine.
BiotechDeep TechDigital HealthMedical DevicesCambridge, US
Jacob Rubens(Chief Executive Officer)in
Co-investorsModi Ventures
BiotechCambridge, US
HOWARD BERNSTEIN(Executive Officer)HOWARD WEISMAN(Executive Officer, Director)
BoardALAN CRANE(Director)ROBERT LANGER(Director)ANUPENDRA SHARMA(Director)HARRY WILCOX(Director)
Co-investorsFlagship VenturesNewpath PartnersPolaris Partners
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases.
BiotechDigital HealthMedical Devices
Geoff von Maltzahn(Founder)inJoseph Romanelli(CEO)
Co-investorsArtis VenturesMarch Capital PartnersOMX VenturesSoftBank Vision FundSolari CapitalToba Capital+4 more
BiotechCambridge, US
Ulrik B. Nielsen(Mr. Nielsen is the President of the Issuer.)Bart Henderson(Mr. Henderson is the CEO and Treasurer of the Issuer.)Doug Lauffenburger(Director)John Dineen(Director)John Hohneker(Director)
BoardDoug Cole(Director)
Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields.
AI & Machine LearningBiotechHealthtech
David Berry(Founder)in
Co-investorsAtinum Investment Co. Ltd.BioGenerator VenturesKoch Disruptive Technologies
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
IPOs and acquisitions across the tracked portfolioGenerate BiomedicinesNASDAQ: GENBSeres TherapeuticsNASDAQ: MCRBSeres HealthNASDAQ: MCRBFoghorn TherapeuticsNASDAQ: FHTXCaringoacq. by DataCore
Portfolio news
latest coverage across their companiesEvelo · tickerreport.com · Aug 30, 2026
Moderna · biopharmadive.com · Aug 28, 2026
Valo · startbase.com · Aug 18, 2026
Generate Biomedicines · stocktitan.net · Aug 6, 2026
Cloudflare Turnstile · marketbeat.com · Jul 18, 2026
Inari · aol.com · Jul 7, 2026
Tessera · erp.today · Jun 26, 2026
Public market activity · per SEC filings
what is this? ⓘ51 insider ownership filings (Forms 3/4/5)
at Generate Biomedicines, Inc. (GENB), Foghorn Therapeutics Inc. (FHTX), Sana Biotechnology, Inc. (SANA), Sigilon Therapeutics, Inc. (SGTX), Evelo Biosciences, Inc. (EVLO), Omega Therapeutics, Inc. (OMGA), Axcella Health Inc. (AXLA), Seres Therapeutics, Inc. (MCRB)
Files 13F institutional holdings reports · latest Aug 2026
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Flagship Pioneering made?
- Flagship Pioneering has 41 tracked investments, 1 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
- What stage does Flagship Pioneering invest at?
- Flagship Pioneering invests at the Seed, Series A stages.
- What is Flagship Pioneering's typical check size?
- Flagship Pioneering typically writes checks of $500K – $10M.
- What sectors does Flagship Pioneering focus on?
- Flagship Pioneering focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Longevity, Sector Agnostic.
- Where is Flagship Pioneering located?
- Flagship Pioneering is headquartered in Cambridge, US.
- Does Flagship Pioneering lead rounds?
- Flagship Pioneering typically participates in rounds rather than leading them.
- Who does Flagship Pioneering co-invest with?
- Flagship Pioneering most often shares deals with ARCH Venture Partners, March Capital Partners, Modi Ventures, among 77 tracked co-investors.
Media · Podcasts & interviews
featuring the teamAvak Kahvejian of Flagship Pioneering at HLTH USA 2025
New York Stock Exchange · Avak Kahvejian
Flagship Pioneering's Noubar Afeyan speaks to new citizens at the JFK Library
John F. Kennedy Library Foundation · Noubar Afeyan
Fireside Chat with Noubar Afeyan, Founder & CEO of Flagship Pioneering
Boston Globe Events · Noubar Afeyan
No Priors Ep. 104 | With Flagship Pioneering CEO and Co-Founder Noubar Afeyan
No Priors: AI, Machine Learning, Tech, & Startups · Noubar Afeyan
Noubar Afeyan: Moderna, AI, Flagship Pioneering, Biotech, Armenia, Lebanon | Episode #007
MIT New Colossus Project · Noubar Afeyan
Founder Stories: Noubar Afeyan, Flagship Pioneering
Axial · Noubar Afeyan
Images
Co-investors · 28
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
.png)
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Lightspeed is a global venture capital firm that has spent over two decades backing innovative companies as an early and first investor.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
Sapphire Ventures partners with expansion-stage enterprise software companies aiming to become category leaders.
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
23andMe Research Institute is a genetic research organization that unites a community of 11 million members to advance health discoveries and deepen understanding of human DNA through collaborative research. The institute operates a cycle where members contribute genetic data that fuels research, which produces insights and breakthroughs that flow back to members and society.
▶16 more co-investors
Tribeca Venture PartnersOrbiMedFlare Capital PartnersNational Grid PartnersTA VenturesJohnson & Johnson Innovation – JJDCCambridge Innovation CapitalThird Rock VenturesAisling CapitalSamsara BioCapital1955 Capital+ND CapitalVensana CapitalBorealis VenturesACORN BIOVENTURESPetri
Firms observed investing alongside Flagship Pioneering, from public investor directories. Shared companies are the overlap with Flagship Pioneering's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Overwater Ventures is an early-stage venture firm that partners with pre-seed and seed stage founders working on large-scale problems, offering hands-on support across launch strategy, go-to-market, fundraising, and marketing.
Draper Associates is an early-stage venture firm that backs bold, visionary founders building transformational businesses ahead of mainstream conviction.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.